Zenas BioPharma Reports Positive Phase 2 Trial Results

Zenas BioPharma, Inc. ( (ZBIO) ) just unveiled an announcement.

On October 27, 2025, Zenas BioPharma announced positive results from its Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis (RMS). The trial demonstrated a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo, indicating a strong inhibitory mechanism of obexelimab. This outcome supports its potential as a significant therapy for autoimmune diseases. The company plans to report further data in early 2026, which could impact future development decisions for obexelimab in RMS.

The most recent analyst rating on (ZBIO) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.

Spark’s Take on ZBIO Stock

According to Spark, TipRanks’ AI Analyst, ZBIO is a Neutral.

The overall stock score for Zenas BioPharma is primarily impacted by its weak financial performance, characterized by declining revenues and significant cash flow challenges. While technical analysis shows positive momentum, the negative P/E ratio and lack of dividend yield weigh down the valuation score. The absence of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on ZBIO stock, click here.

More about Zenas BioPharma, Inc.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing transformative therapies for autoimmune diseases. The company is advancing two late-stage potential franchise molecules, obexelimab and orelabrutinib, aimed at providing superior clinical benefits to patients with autoimmune conditions.

Average Trading Volume: 282,138

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.01B

See more insights into ZBIO stock on TipRanks’ Stock Analysis page.